19 results about "Artificial protein" patented technology

The present invention relates to a synthetic peptide comprising the following elements from the N-terminus to the C-terminus: a) a first cell-penetrating peptide or functional fragments or derivatives, or biologically active variants thereof and b) a second peptide with agonist activity of OR1 and OR2 receptors or functional fragments or derivatives, or biologically active variants thereof.

The present invention relates to an artificial fur and a method for manufacturing the same, and aims to provide an artificial fur which has sufficient moisture absorption performance and can reduce the energy consumption required for manufacturing. The artificial fur according to the present invention contains artificial protein fibers.

The application provides a method and system capable of end-to-end protein design and analysis verification, and can generate protein or protein complex structure and sequence according to specific requirements, and the method comprises the following steps: performing loss calculation on the three-dimensional structure of the initialized protein sequence obtained through the structure prediction algorithm independently developed by the company based on confidence, stability, target correlation; continuously improving the designed protein sequence and structure based on the Markov chain Monte Carlo algorithm or gradient regression according to the obtained loss; and putting the designed protein structure into a sequence design model to optimize the side chain, and obtaining the optimal candidate protein through screening. The method can train the model to be specific and automatic for protein design, and can generate a new artificial protein which is completely different from natural protein in structure and sequence.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

Disclosed is a printing ink including a fixing agent including a peptide polymer (having a polypeptide chain), a liquid medium, and a colorant. Also disclosed is a method of manufacturing a printed matter, the method comprising: a step of forming a film containing a printing ink on a substrate by a printing process; and removing the solvent from the film to form a printed film containing the fixing agent and the coloring agent. The polypeptide chain may also include an artificial protein.

The invention belongs to the technical field of bioengineering and application thereof, and particularly relates to fucoidanase based on ancestor sequence reconstruction and application of the fucoidanase. An assumed artificial protein with endo-1, 3-fucosan activity is constructed through an ancestor sequence reconstruction strategy, so that the artificial endo-1, 3-fucosan enzyme which is completely different from a fucosan enzyme sequence of a natural source is obtained, and the amino acid sequence of the artificial endo-1, 3-fucosan enzyme is SEQ ID NO. 1. The fucoidanase can be used for degrading fucoidan from various sources in an incision manner, and under the condition of controlling the enzyme addition amount or the reaction time, the fucoidan can be quickly degraded within 10 minutes to generate fucoidan oligosaccharide with a specific structure.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen-targeted artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Maraba virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Maraba virus envelope provided by the invention can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed on the basis of the mutated Maraba virus envelope protein has better stability in serum, and can be used for preparing a novel lentiviral vector of the mutated Maraba virus envelope. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The invention discloses recombinant escherichia coli with high yield of cyanidin-3-O-glucoside as well as a construction method and application of the recombinant escherichia coli. The method comprises the following steps: by taking escherichia coli BL21 (DE3) engineering bacteria as a host, integrating flavanonol 4-reductase, anthocyanin synthetase and flavonoid 3-O-glucosyltransferase from different sources onto a plasmid vector pRSFDuet, and constructing to obtain a chassis cell for producing C3G; meanwhile, glutathione transferase is overexpressed, dissolution-promoting tag small ubiquitin-like modified protein is added, FaDFR is modified through enzyme engineering, FaDFR catalytic efficiency is improved through artificial protein cage space combination pathway enzyme, key precursor UDP-glucose is synthesized in an in-situ intensified mode and cofactor engineering, the cell factory for efficiently synthesizing C3G is constructed based on the combination strategy, the yield of C3G is increased, and the method has the advantages that the method is simple and convenient to operate, and the cost is low. The titer reaches 797.20 mg / L. The method provided by the invention has the characteristics of simplicity, economy and eco-friendliness.

A block copolymer or the like, having: a first segment containing a protein structure; and one or more second segments containing a molecular group having a plasticizing function for the protein structure and bound to the first segment, in the block copolymer, the protein structure is a protein structure containing a main sequence, and a hydrophobic tag bound to the N-terminal and C-terminal of the main sequence, and having at least two reactive points that react with a compound having the second segment and a reactive group, the reactive point closest to the N-terminal side among the reactive points is present within the hydrophobic tag on the N-terminal side, or is NH2 as the N-terminal of the protein structure, or is present within the main sequence, the reactive point closest to the C-terminal side among the reactive points is present within the hydrophobic tag on the C-terminal side, or is present within 9 residues from the C-terminal of the main sequence.

Described herein is a method for generating an artificial protein, comprising: training an immunogenicity conditioner to predict one or more lymphocyte receptor sequences that recognize one or more target molecules; using a gradient computed using one or more parameters of the immunogenicity conditioner to guide a generative process of protein design, wherein the gradient is computed to guide the design of the artificial protein such that the artificial protein is recognized by a target set of the one or more of lymphocyte receptor sequences; testing the recognition of the resulting artificial protein by one or more of the lymphocyte receptor sequences using an experimental assay.

The present invention relates to a method for enhancing the folding of disulfide-bonded proteins in E. coli. The method for activating a disulfide-bonded protein in E coli according to the present invention enables a disulfide bond-requiring protein to be stably folded and activated in E coli without a separate refolding process by utilizing an artificial protein endowed with redox capability. Accordingly, the method allows for the efficient production of disulfide-bonded proteins, which have been difficult to express in E coli in the past, thereby providing advantages for large-scale industrial application and pharmaceutical development involving disulfide-bonded proteins.

The application artificially designs and creates a functional module SyKerMb with high efficient degradation of poultry feather waste and synthesis of new heme protein by using synthetic biology method. The application constructs a recombinant vector of the functional module, and assembles and expresses the same in a chassis microbial cell Escherichia coli. Experiments prove that the engineered strain integrated with the conversion functional module has the biological synthesis capacity of degrading animal waste feather and efficiently synthesizing artificial heme protein, and can be used in artificial protein preparation and future artificial food and other related industrial production.

The present invention provides a protein including an amino acid sequence that has at least 80% identity with the amino acid sequence represented by SEQ ID NO: 7 or 8. The protein has suppressed silicic acid transport activity.

The invention discloses a preparation method and application of an artificial protein essential oil microcapsule, and the preparation method comprises the following steps: S1, selecting proper artificial protein to prepare a wall material of the microcapsule, and utilizing a complex coacervation method to react with a capsule wall polymer in a stirring process to form a covalent bond network; the microcapsules are directly stored in the form of aqueous dispersion; s2, adding an anionic emulsifier into the softened water, and uniformly stirring to form a water phase; s3, slowly adding the oil phase into the water phase, and stirring at a high speed to form an emulsion. According to the invention, the essential oil is wrapped in the microcapsules, so that the volatilization speed of the essential oil is delayed, the binding strength of the essential oil and the textile is enhanced, and the microcapsules do not fall off; when the essential oil is applied to textiles, the durability and the stability of the essential oil are effectively improved; the textile has the functions of lasting fragrance, antibiosis, soothing and the like, the cost of after-finishing of the textile is reduced, and the adsorption capacity of the textile to essential oil is improved.

The invention relates to the technical field of bioinformatics, and discloses a novel single-stranded DNA (deoxyribonucleic acid) deaminase mining method, system, equipment and medium, which break through the limitation that the traditional homologous search has low sensitivity to distant proteins and depends on random experimental verification by utilizing a deaminase family characteristic HMM (Hidden Markov Model) spectrum and combining a deaminase editing activity prediction model. The novel single-stranded DNA deaminase with editing activity can be efficiently mined from massive natural or artificial protein data. According to the method, the accuracy and coverage range of candidate protein screening are remarkably improved, a high-quality core element is provided for developing a high-specificity and low-off-target base editor, meanwhile, design optimization of a multifunctional editor is supported, and the method has important application value in the fields of gene therapy, molecular breeding and the like.

In some embodiments, a computer-implemented method of generating one or more artificial amino acid sequences representing artificial proteins predicted to have a different level of stability than a protein represented by an input amino acid sequence is provided. A computing system receives the input amino acid sequence and uses a tuned base machine learning model to generate an encoding of the input amino acid sequence. The tuned base machine learning model was fine-tuned to encode characteristics of proteins having the different level of stability. The computing system generates the one or more artificial amino acid sequences by decoding the encoding of the input amino acid sequence.

The present disclosure relates to a device and method for virtual reality interaction based on bimanual gestures for artificial protein backbone design, wherein the device is configured to detect a bimanual gesture of a user gripping a same virtual central axis in a space, and generate a protein secondary structure corresponding to the bimanual gesture along the virtual central axis in the space. In the present disclosure, the protein secondary structure may include at least one of an alpha-helix, a beta-strand, or a loop. In various embodiments, the bimanual gesture may include at least one of a grab gesture, a thumb-grab gesture, or a pinch gesture.

To provide a novel method for producing artificial protein fibers, and a novel artificial protein solution not seen before. [Solution] A method for producing artificial protein fibers by coagulating a dope solution in a coagulation solution, wherein the dope solution is an artificial protein solution obtained by dissolving only artificial protein as a fiber-forming material in an aqueous solution of N-methylmorpholine N-oxide, and the content of the artificial protein relative to the entire artificial protein solution is 30% by weight or less.

The large-sized CRISPR Cas proteins have hindered the effective use of CRISPR-mediated gene editing in human therapeutics due to the lack of delivery strategies for these large-sized proteins to reach their target locations. As the use of highly targeted medicine increases, health care related business and individuals seek additional ways to more efficiently develop personalized medicine. CRISPR technologies revolutionized the gene therapy field in the past decade. AI-based tools to optimize the size of Cas proteins as well as developed gene-editing tools of experimentally-validated artificial-designed mini-Cas proteins were developed; thereby, shifting the paradigm of CRISPR research field from searching for new Cas proteins in nature to designing artificial Cas using AI algorithms.